Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Shares Issued (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Shares Issued for 6 consecutive years, with -$12.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 65.39% to -$12.8 million in Q4 2025 year-over-year; TTM through Sep 2025 was -$24.2 million, a 146.82% decrease, with the full-year FY2024 number at $11.8 million, up 312.24% from a year prior.
  • Shares Issued was -$12.8 million for Q4 2025 at Kymera Therapeutics, down from -$711000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $33.8 million in Q2 2024 to a low of -$36.9 million in Q4 2024.
  • A 5-year average of $1.4 million and a median of $1.3 million in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 276.98% in 2023, then tumbled 1391.96% in 2024.
  • Kymera Therapeutics' Shares Issued stood at $1.8 million in 2021, then plummeted by 191.92% to -$1.6 million in 2022, then skyrocketed by 276.98% to $2.9 million in 2023, then crashed by 1391.96% to -$36.9 million in 2024, then soared by 65.39% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Shares Issued are -$12.8 million (Q4 2025), -$711000.0 (Q3 2025), and $13.0 million (Q2 2025).